MX2017004762A - Uso de cannabinoides en el tratamiento de epilepsia. - Google Patents
Uso de cannabinoides en el tratamiento de epilepsia.Info
- Publication number
- MX2017004762A MX2017004762A MX2017004762A MX2017004762A MX2017004762A MX 2017004762 A MX2017004762 A MX 2017004762A MX 2017004762 A MX2017004762 A MX 2017004762A MX 2017004762 A MX2017004762 A MX 2017004762A MX 2017004762 A MX2017004762 A MX 2017004762A
- Authority
- MX
- Mexico
- Prior art keywords
- syndrome
- cbd
- treatment
- cannabinoids
- epilepsy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Abstract
La presente descripción se refiere al uso de cannabidiol (CBD) para el tratamiento de las crisis atónicas. En particular, el CBD parece particularmente eficaz en la reducción de las crisis atónicas en pacientes que sufren de etiologías que incluyen: Síndrome de Lennox-Gastaut; Complejo de Esclerosis Tuberosa; Síndrome de Dravet; Síndrome de Doose; Síndrome de Aicardi; CDKL5 y Dup15q en comparación con otros tipos de crisis. La descripción se refiere además al uso de CBD en combinación con uno o más fármacos antiepilépticos (AEDs).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1418171.3A GB2531282A (en) | 2014-10-14 | 2014-10-14 | Use of cannabinoids in the treatment of epilepsy |
PCT/GB2015/053028 WO2016059403A1 (en) | 2014-10-14 | 2015-10-14 | Use of cannabinoids in the treatment of epilepsy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017004762A true MX2017004762A (es) | 2017-07-27 |
Family
ID=52001393
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017004762A MX2017004762A (es) | 2014-10-14 | 2015-10-14 | Uso de cannabinoides en el tratamiento de epilepsia. |
MX2020006951A MX2020006951A (es) | 2014-10-14 | 2017-04-11 | Uso de cannabinoides en el tratamiento de epilepsia. |
MX2023003337A MX2023003337A (es) | 2014-10-14 | 2017-04-11 | Uso de cannabinoides en el tratamiento de epilepsia. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006951A MX2020006951A (es) | 2014-10-14 | 2017-04-11 | Uso de cannabinoides en el tratamiento de epilepsia. |
MX2023003337A MX2023003337A (es) | 2014-10-14 | 2017-04-11 | Uso de cannabinoides en el tratamiento de epilepsia. |
Country Status (20)
Country | Link |
---|---|
US (12) | US10111840B2 (es) |
EP (2) | EP3735964A1 (es) |
JP (4) | JP6656241B2 (es) |
AU (3) | AU2015332212B2 (es) |
BR (1) | BR112017007777A2 (es) |
CA (2) | CA3232241A1 (es) |
CY (1) | CY1123229T1 (es) |
DK (1) | DK3206716T3 (es) |
ES (1) | ES2811327T3 (es) |
GB (1) | GB2531282A (es) |
HR (1) | HRP20201230T1 (es) |
HU (1) | HUE053262T2 (es) |
IL (3) | IL296865A (es) |
LT (1) | LT3206716T (es) |
MX (3) | MX2017004762A (es) |
PL (1) | PL3206716T3 (es) |
PT (1) | PT3206716T (es) |
RS (1) | RS60767B1 (es) |
SI (1) | SI3206716T1 (es) |
WO (1) | WO2016059403A1 (es) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Gw伐瑪有限公司 | 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途 |
GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531281A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
CA2974895A1 (en) * | 2015-01-25 | 2016-07-28 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
CA2992427A1 (en) * | 2015-04-28 | 2016-11-03 | The Regents Of The University Of California | Uses of cannabidiol for treatment of infantile spasms |
GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
JP2019507111A (ja) | 2015-12-22 | 2019-03-14 | ゾゲニクス インターナショナル リミテッド | 代謝抵抗性フェンフルラミン類縁体およびその使用法 |
GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
EP3471746A4 (en) | 2016-06-15 | 2020-02-26 | India Globalization Capital, Inc. | METHOD AND COMPOSITION FOR TREATING EPILEPTIC DISORDERS |
GB2551985B (en) * | 2016-07-01 | 2019-01-30 | Gw Res Ltd | Novel formulation |
GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
RU2021106383A (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
GB2557921A (en) * | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
GB2568471B (en) * | 2017-11-15 | 2022-04-13 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2568929A (en) * | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2569961B (en) * | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
GB2572126B (en) * | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
GB2572737A (en) * | 2018-01-24 | 2019-10-16 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
CA3089994A1 (en) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Hemp powder |
GB201806953D0 (en) * | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
US11571397B2 (en) | 2018-05-11 | 2023-02-07 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
WO2020077153A1 (en) | 2018-10-10 | 2020-04-16 | Canopy Holdings, LLC | Synthesis of cannabigerol |
GB2579179A (en) * | 2018-11-21 | 2020-06-17 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
GB2580881A (en) * | 2018-11-30 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2580653A (en) * | 2019-01-21 | 2020-07-29 | Gw Res Ltd | Use of cannabinoids in the treatment of comorbidities associated with epilepsy |
GB2583526A (en) * | 2019-05-03 | 2020-11-04 | Gw Res Ltd | Use of cannabidiol in the treatment of tuberous sclerosis complex |
US20200397749A1 (en) * | 2019-06-18 | 2020-12-24 | Opiant Pharmaceuticals, Inc. | Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist |
US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
GB2588457B (en) * | 2019-10-25 | 2022-12-21 | Gw Res Ltd | Cannabinoid compound |
GB2589306A (en) * | 2019-10-25 | 2021-06-02 | Gw Res Ltd | Use of cannabidiol preparations in the treatment of fragile X syndrome |
GB2588456B (en) * | 2019-10-25 | 2023-02-01 | Gw Res Ltd | Cannabinoid compound |
GB201916977D0 (en) * | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
CN114760976A (zh) | 2019-12-16 | 2022-07-15 | 高露洁-棕榄公司 | 含有菊粉的口腔护理组合物 |
GB201918846D0 (en) * | 2019-12-19 | 2020-02-05 | Gw Res Ltd | Oral cannabinoid formulations |
GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
GB2597297A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
GB2597308A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
GB2597312A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2597318A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2597298A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with brain damage |
GB2597306A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2597310A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2597290A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2597299A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
GB2597320A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2597283A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
GB2597302A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage |
GB2597313A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2600077A (en) * | 2020-07-20 | 2022-04-27 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2597309A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2597317A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2597301A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with herpes simplex virus |
GB2597304A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome |
WO2022017936A1 (en) * | 2020-07-20 | 2022-01-27 | GW Research Limited | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
GB2597280A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with auriculotemporal syndrome |
GB2597311A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2599340A (en) * | 2020-07-20 | 2022-04-06 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
US12029720B2 (en) | 2021-04-29 | 2024-07-09 | Tilray Brands, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
WO2023007152A1 (en) * | 2021-07-28 | 2023-02-02 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US12036228B2 (en) | 2022-04-12 | 2024-07-16 | Shackelford Pharma Inc. | Treatment of seizure disorders |
US11944635B1 (en) | 2023-07-24 | 2024-04-02 | Poviva Corp | Compositions and methods for treating epilepsy |
US12023346B1 (en) | 2023-07-24 | 2024-07-02 | Poviva Corp | Compositions and methods for treating epilepsy |
US11931369B1 (en) | 2023-07-24 | 2024-03-19 | Poviva Corp | Compositions and methods for treating epilepsy |
US11986485B1 (en) | 2023-07-24 | 2024-05-21 | Poviva Corp | Compositions and methods for treating epilepsy |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1011184A (en) | 1909-10-18 | 1911-12-12 | Joseph H Godfrey | Bottle-filling device. |
US1009252A (en) | 1910-11-26 | 1911-11-21 | Michael E Mallo | Carbureter. |
US1013709A (en) | 1911-05-22 | 1912-01-02 | New Orleans Specialty Co | Game apparatus. |
US2304669A (en) | 1940-08-16 | 1942-12-08 | Adams Roger | Isolation of cannabidiol |
GB9726916D0 (en) | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
WO1999053917A1 (en) * | 1998-04-21 | 1999-10-28 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cannabinoids as antioxidants and neuroprotectants |
US6403126B1 (en) | 1999-05-26 | 2002-06-11 | Websar Innovations Inc. | Cannabinoid extraction method |
US6949582B1 (en) | 1999-05-27 | 2005-09-27 | Wallace Walter H | Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment |
IL136839A (en) | 2000-06-16 | 2006-12-10 | Yissum Res Dev Co | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
DE10051427C1 (de) | 2000-10-17 | 2002-06-13 | Adam Mueller | Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte |
HU227452B1 (en) | 2001-02-14 | 2011-06-28 | Gw Pharma Ltd | Mucoadhesive pharmaceutical formulation |
GB2381194A (en) | 2001-09-07 | 2003-04-30 | Gw Pharmaceuticals Ltd | Pharmaceutical formulations |
GB2377633A (en) | 2001-05-11 | 2003-01-22 | Gw Pharmaceuticals Ltd | Pharmaceutical compositions comprising the cannabinoids THC and CBD |
GB2380129B (en) | 2001-02-14 | 2004-08-11 | Gw Pharma Ltd | Pharmaceutical formulations |
US7025992B2 (en) | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
GB2377218A (en) | 2001-05-04 | 2003-01-08 | Gw Pharmaceuticals Ltd | Process and apparatus for extraction of active substances and enriched extracts from natural products |
GB2381450B (en) | 2001-10-31 | 2006-05-31 | Gw Pharma Ltd | Compositions for administration of natural or synthetic cannabinoids by vaporisation |
GB0202385D0 (en) | 2002-02-01 | 2002-03-20 | Gw Pharma Ltd | Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions |
ITPD20020138A1 (it) | 2002-05-24 | 2003-11-24 | Matteo Bevilacqua | Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima. |
DE10226494A1 (de) | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
PT1542657E (pt) | 2002-08-14 | 2012-02-29 | Gw Pharma Ltd | Formulações líquidas canabinóides para administração pela mucosa |
US10538373B2 (en) | 2002-08-14 | 2020-01-21 | Gw Pharma Limited | Pharmaceutical formulation |
US6946150B2 (en) | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
CA2823474A1 (en) | 2002-08-14 | 2004-02-14 | Gw Pharma Limited | Botanical drug substances comprising various proportions of thc and cbd |
US6986748B2 (en) | 2002-08-15 | 2006-01-17 | Scimed Life Systems, Inc. | Multiple biopsy apparatus and related method of use |
GB0222077D0 (en) | 2002-09-23 | 2002-10-30 | Gw Pharma Ltd | Methods of preparing cannabinoids from plant material |
GB2393182B (en) * | 2002-09-23 | 2007-03-14 | Gw Pharma Ltd | Method of preparing cannabidiol from plant material |
US20040110828A1 (en) | 2002-11-27 | 2004-06-10 | Chowdhury Dipak K. | Tetrahydrocannabinol compositions and methods of manufacture and use thereof |
IL160420A0 (en) | 2004-02-16 | 2004-07-25 | Yissum Res Dev Co | Treating or preventing diabetes with cannabidiol |
WO2006017892A1 (en) | 2004-08-16 | 2006-02-23 | Northern Sydney And Central Coast Area Health Service | Methods for improving cognitive functioning |
WO2006054057A2 (en) | 2004-11-16 | 2006-05-26 | Gw Pharma Limited | New use for cannabinoid |
GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
US20070060638A1 (en) | 2005-08-26 | 2007-03-15 | Olmstead Mary C | Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist |
GB2432312A (en) | 2005-11-01 | 2007-05-23 | Gw Pharma Ltd | Pharmaceutical compositions for the treatment of pain |
GB2434312B (en) | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
US9877928B2 (en) | 2006-05-30 | 2018-01-30 | Air Systems, Inc. | Gear drive damper |
GB2438682A (en) | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
EP2046290A4 (en) | 2006-08-04 | 2011-08-17 | Insys Therapeutics Inc | AQUEOUS DRONABINOL FORMULATIONS |
WO2008021394A2 (en) | 2006-08-15 | 2008-02-21 | Theraquest Biosciences, Llc | Pharmaceutical formulations of cannabinoids and method of use |
WO2008061160A1 (en) | 2006-11-14 | 2008-05-22 | Pharmacyclics, Inc. | Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions |
WO2008094181A2 (en) | 2007-02-01 | 2008-08-07 | The Regents Of The University Of Michigan | Compositions and methods for detecting, preventing and treating seizures and seizure related disorders |
CN101040855A (zh) | 2007-04-12 | 2007-09-26 | 杨喜鸿 | 含有利莫那班和泊洛沙姆的组合物、固体分散体及其制备和药物应用 |
GB2448535A (en) | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
US9084771B2 (en) | 2007-05-17 | 2015-07-21 | Sutter West Bay Hospitals | Methods and compositions for treating cancer |
GB2449691A (en) | 2007-05-31 | 2008-12-03 | Gw Pharma Ltd | A reference plant lacking medicinal active compound expression |
GB2450753B (en) | 2007-07-06 | 2012-07-18 | Gw Pharma Ltd | New Pharmaceutical formulation |
EP2023121A1 (en) | 2007-07-06 | 2009-02-11 | Bp Oil International Limited | Optical cell |
CA2694325C (en) * | 2007-07-30 | 2015-09-22 | Alltranz Inc. | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
JP2010535774A (ja) | 2007-08-06 | 2010-11-25 | インシス セラピューティクス インコーポレイテッド | 経口カンナビノイド液体製剤および治療方法 |
GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
GB2459637B (en) | 2008-01-21 | 2012-06-06 | Gw Pharma Ltd | New use for cannabinoids |
BRPI0910094B1 (pt) | 2008-03-26 | 2021-08-10 | Stichting Sanammad | Composição de goma de mascar, e, blíster |
GB2478074B (en) | 2008-06-04 | 2012-12-26 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
GB2478072B (en) | 2008-06-04 | 2012-12-26 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
EP2341903A1 (en) | 2008-07-31 | 2011-07-13 | Bionorica Research GmbH | Cannabinoids for use in treating or preventing cognitive impairment and dementia |
ES2622582T3 (es) | 2008-10-31 | 2017-07-06 | University Of Mississippi | Proceso para la preparación de ésteres de delta-9-THC-aminoácido |
WO2010126501A1 (en) | 2009-04-29 | 2010-11-04 | University Of Kentucky Research Foundation | Cannabinoid-containing compositions and methods for their use |
WO2011002285A1 (en) | 2009-06-29 | 2011-01-06 | Bender Analytical Holding B.V. | Drug delivery system comprising polyoxazoline and a bioactive agent |
GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
US8735374B2 (en) | 2009-07-31 | 2014-05-27 | Intelgenx Corp. | Oral mucoadhesive dosage form |
GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
GB2479153B (en) | 2010-03-30 | 2014-03-19 | Gw Pharma Ltd | The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy |
TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Gw伐瑪有限公司 | 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途 |
GB2487183B (en) | 2011-01-04 | 2018-10-03 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
US20130143894A1 (en) | 2010-06-07 | 2013-06-06 | vadel Pharma Inc. | Oral spray formulations ad methods for administration of sildenafil |
JP5792299B2 (ja) | 2010-08-04 | 2015-10-07 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 神経因性疼痛の治療のための6’−フルオロ−(N−メチル−又はN,N−ジメチル−)−4−フェニル−4’,9’−ジヒドロ−3’H−スピロ[シクロヘキサン−1,1’−ピラノ[3,4,b]インドール]−4−アミンを含む医薬剤形 |
WO2012033478A1 (en) | 2010-09-07 | 2012-03-15 | Murty Pharmaceuticals, Inc. | An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
GB2487712B (en) * | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
CA2737447A1 (en) | 2011-04-27 | 2012-10-27 | Antony Paul Hornby | Hayley's comet |
US9104993B2 (en) | 2011-04-28 | 2015-08-11 | Lantronix, Inc. | Asset management via virtual tunnels |
GB2524689B (en) | 2011-05-20 | 2016-01-27 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
GB201111261D0 (en) | 2011-07-01 | 2011-08-17 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders |
WO2013032351A1 (en) | 2011-08-26 | 2013-03-07 | BIAL - PORTELA & Cª, S.A. | Treatments involving eslicarbazepine acetate or eslicarbazepine |
GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
GB2496687A (en) | 2011-11-21 | 2013-05-22 | Gw Pharma Ltd | Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells |
US9254272B2 (en) | 2011-11-30 | 2016-02-09 | Sutter West Bay Hospitals | Resorcinol derivatives |
DE102012105063C5 (de) | 2012-06-12 | 2023-09-14 | Thc Pharm Gmbh The Health Concept | Stabilisierung von Cannabinoiden und deren pharmazeutischen Zubereitungen |
US9345771B2 (en) | 2012-10-04 | 2016-05-24 | Insys Development Company, Inc. | Oral cannabinoid formulations |
CN103110582A (zh) | 2013-03-04 | 2013-05-22 | 上海医药工业研究院 | 大麻酚类化合物微乳剂及其制备方法 |
WO2014145490A2 (en) | 2013-03-15 | 2014-09-18 | Biotech Institute, Llc | Breeding, production, processing and use of specialty cannabis |
ES2781756T3 (es) | 2013-03-19 | 2020-09-07 | Univ Pompeu Fabra | Antagonistas del receptor de canabinoide CB1 para la utilización en el tratamiento de enfermedades asociadas a anormalidades dendríticas neuronales |
US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
US20150181924A1 (en) | 2013-10-31 | 2015-07-02 | Michael R. Llamas | Cannabidiol liquid composition for smoking |
US9259449B2 (en) | 2014-01-07 | 2016-02-16 | Joshua Michael Raderman | Method for modifying THC content in a lipid-based extract of cannabis |
US10052339B2 (en) | 2014-03-21 | 2018-08-21 | Bodybio Inc. | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids |
US20170224634A1 (en) | 2014-05-29 | 2017-08-10 | Insys Development Company, Inc. | Stable cannabinoid formulations |
US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
JP6659933B2 (ja) | 2014-05-29 | 2020-03-04 | フレッシュ・カット・ディベロップメント・エル・エル・シー | 安定なカンナビノイド製剤 |
WO2015187988A1 (en) | 2014-06-04 | 2015-12-10 | Intellimedix | Composition and methods of treating epilepsy and/or epilepsy-related disorders |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
WO2016022936A1 (en) | 2014-08-07 | 2016-02-11 | Murty Pharmaceuticals, Inc. | An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts |
CA2859934A1 (en) | 2014-09-22 | 2016-03-22 | A. Paul Hornby | Hayley's comet ii |
GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2531280A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
US9730911B2 (en) | 2014-10-21 | 2017-08-15 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
AU2015351937A1 (en) | 2014-11-26 | 2017-06-29 | One World Cannabis Ltd | Synergistic use of cannabis for treating multiple myeloma |
US9622145B2 (en) | 2014-12-05 | 2017-04-11 | At&T Intellectual Property I, L.P. | Wireless network architecture for providing media content |
US10172786B2 (en) | 2014-12-16 | 2019-01-08 | Axim Biotechnologies, Inc. | Oral care composition comprising cannabinoids |
CA2974895A1 (en) | 2015-01-25 | 2016-07-28 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
US20160338974A1 (en) | 2015-03-02 | 2016-11-24 | Afgin Pharma, Llc | Topical regional neuro affective therapy with cannabinoid combination products |
AU2016226267A1 (en) | 2015-03-02 | 2017-09-28 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoids |
AU2016231788A1 (en) | 2015-03-19 | 2017-10-12 | One World Cannabis Ltd | Preparations of cannabis emulsions and methods thereof |
WO2016199148A1 (en) | 2015-06-11 | 2016-12-15 | One World Cannabis Ltd | Novel cannabinoid combination therapies for multiple myeloma (mm) |
GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
GB2551985B (en) | 2016-07-01 | 2019-01-30 | Gw Res Ltd | Novel formulation |
GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
US10925525B2 (en) | 2017-08-18 | 2021-02-23 | Canon U.S.A., Inc. | Combined pulse oximetry and diffusing wave spectroscopy system and control method therefor |
GB201715919D0 (en) | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
GB2568471B (en) | 2017-11-15 | 2022-04-13 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2572125B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
GB2572126B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
GB2572737A (en) | 2018-01-24 | 2019-10-16 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
GB2579179A (en) | 2018-11-21 | 2020-06-17 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
GB2580881A (en) | 2018-11-30 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2580653A (en) | 2019-01-21 | 2020-07-29 | Gw Res Ltd | Use of cannabinoids in the treatment of comorbidities associated with epilepsy |
GB2581517A (en) | 2019-02-22 | 2020-08-26 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2581987B (en) | 2019-03-06 | 2021-11-17 | Gw Res Ltd | Use of cannabidiol in combination with antibiotics |
GB2584140A (en) | 2019-05-23 | 2020-11-25 | Gw Res Ltd | Use of cannabidiol in the treatment of epileptic spasms |
GB2584341B (en) | 2019-05-31 | 2023-03-01 | Gw Res Ltd | Cannabinoid formulations |
GB2586026A (en) | 2019-07-29 | 2021-02-03 | Gw Res Ltd | Use of cannabidol in the treatment of Dravet syndrome |
GB201916977D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US20220087951A1 (en) | 2020-09-18 | 2022-03-24 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
-
2014
- 2014-10-14 GB GB1418171.3A patent/GB2531282A/en not_active Withdrawn
-
2015
- 2015-10-13 US US14/881,969 patent/US10111840B2/en active Active
- 2015-10-14 PL PL15784111T patent/PL3206716T3/pl unknown
- 2015-10-14 ES ES15784111T patent/ES2811327T3/es active Active
- 2015-10-14 LT LTEP15784111.5T patent/LT3206716T/lt unknown
- 2015-10-14 JP JP2017520530A patent/JP6656241B2/ja active Active
- 2015-10-14 EP EP20182071.9A patent/EP3735964A1/en active Pending
- 2015-10-14 CA CA3232241A patent/CA3232241A1/en active Pending
- 2015-10-14 HU HUE15784111A patent/HUE053262T2/hu unknown
- 2015-10-14 DK DK15784111.5T patent/DK3206716T3/da active
- 2015-10-14 WO PCT/GB2015/053028 patent/WO2016059403A1/en active Application Filing
- 2015-10-14 AU AU2015332212A patent/AU2015332212B2/en active Active
- 2015-10-14 MX MX2017004762A patent/MX2017004762A/es active IP Right Grant
- 2015-10-14 SI SI201531315T patent/SI3206716T1/sl unknown
- 2015-10-14 IL IL296865A patent/IL296865A/en unknown
- 2015-10-14 EP EP15784111.5A patent/EP3206716B1/en active Active
- 2015-10-14 RS RS20200940A patent/RS60767B1/sr unknown
- 2015-10-14 BR BR112017007777-9A patent/BR112017007777A2/pt not_active Application Discontinuation
- 2015-10-14 CA CA2963208A patent/CA2963208A1/en active Pending
- 2015-10-14 PT PT157841115T patent/PT3206716T/pt unknown
- 2015-10-14 IL IL281793A patent/IL281793B2/en unknown
-
2017
- 2017-03-03 US US15/449,402 patent/US10092525B2/en active Active
- 2017-03-03 US US15/449,535 patent/US10137095B2/en active Active
- 2017-04-03 IL IL251529A patent/IL251529B/en active IP Right Grant
- 2017-04-11 MX MX2020006951A patent/MX2020006951A/es unknown
- 2017-04-11 MX MX2023003337A patent/MX2023003337A/es unknown
-
2018
- 2018-11-21 US US16/198,141 patent/US10849860B2/en active Active
-
2019
- 2019-09-13 US US16/570,220 patent/US10709673B2/en active Active
- 2019-11-08 US US16/678,961 patent/US10709674B2/en active Active
-
2020
- 2020-02-03 JP JP2020016193A patent/JP2020073580A/ja active Pending
- 2020-06-25 US US16/911,914 patent/US10966939B2/en active Active
- 2020-08-06 HR HRP20201230TT patent/HRP20201230T1/hr unknown
- 2020-08-10 CY CY20201100743T patent/CY1123229T1/el unknown
-
2021
- 2021-03-11 US US17/198,965 patent/US11096905B2/en active Active
- 2021-04-27 US US17/242,075 patent/US11154517B2/en active Active
- 2021-06-25 AU AU2021204353A patent/AU2021204353B2/en active Active
- 2021-09-16 US US17/477,172 patent/US11446258B2/en active Active
-
2022
- 2022-03-02 JP JP2022031730A patent/JP2022066354A/ja active Pending
- 2022-08-11 US US17/819,046 patent/US11633369B2/en active Active
-
2023
- 2023-03-20 US US18/186,792 patent/US20230248664A1/en active Pending
- 2023-11-02 AU AU2023258400A patent/AU2023258400A1/en active Pending
- 2023-11-24 JP JP2023199214A patent/JP2024012681A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020006951A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
MX2022004851A (es) | Uso de cannabidiol para el tratamiento de epilepsia. | |
MX2020006954A (es) | Uso del cannabidiol en el tratamiento del complejo de esclerosis tuberosa. | |
PH12017502104A1 (en) | Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies | |
PH12017500442A1 (en) | Combination therapies with anti-cd38 antibodies | |
IN2014DE02409A (es) | ||
WO2015071474A3 (en) | Crispr-cas system materials and methods | |
MX2021008044A (es) | Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2. | |
MX2016016800A (es) | Metodos para el tratamiento del sobrepeso o la obesidad. | |
WO2012125749A3 (en) | INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS | |
PH12014501032A1 (en) | 2-thiopyrimidinones | |
WO2014145897A3 (en) | Immunotherapy system and method thereof | |
MX2016015569A (es) | Metodos y composiciones para inmunomodulacion. | |
WO2016027029A3 (fr) | Procédé pour déterminer le pronostic de survie d'un patient atteint d'un cancer du pancréas | |
MX362391B (es) | Métodos de tratamiento de enfermedad renal y otros trastornos. | |
PH12017501897A1 (en) | 2-thiopyrimidinones | |
PH12017500084A1 (en) | Vitamin b2 and its use | |
Tangchitsomkid et al. | Comparison of Extraction Methods for Extraction of Migratory Endoparasitic Nematodes from Roots. | |
UA91071U (uk) | Спосіб профілактики та корекції запальних хвороб на донозологічному рівні | |
TH1501004617B (th) | ระบบและวิธีการบีบขยายเพื่อลดคลื่นรบกวนเมื่อแจงหน่วยโดยใช้ส่วนขยาย ตามสเปกตรัมแบบก้าวหน้า | |
UA89119U (uk) | Спосіб лікування антифосфоліпідного синдрому | |
UA86320U (uk) | Мазь котенка для лікування ран різного походження |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |